The role of ketamine in major depressive disorders: Effects on parvalbumin-positive interneurons in hippocampus

Autores
Barrutieta Arberas, I.; Ortuzar, N.; Vaquero Rodríguez, A.; Picó-Gallardo, M.; Bengoetxea, H.; Guevara, M. A.; Gargiulo, Pascual Angel; Lafuente, J. V.
Año de publicación
2023
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Major depressive disorder (MDD) is a complex illness that is arising as a growing public health concern. Although several brain areas are related to this type of disorders, at the cellular level, the parvalbumin-positive cells of the hippocampus interplay a very relevant role. They control pyramidal cell bursts, neuronal networks, basic microcircuit functions, and other complex neuronal tasks involved in mood disorders. In resistant depressions, the efficacy of current antidepressant treatments drops dramatically, so the new rapid-acting antidepressants (RAADs) are being postulated as novel treatments. Ketamine at subanesthetic doses and its derivative metabolites have been proposed as RAADs due to their rapid and sustained action by blocking N-methyl-d-aspartate (NMDA) receptors, which in turn lead to the release of brain-derived neurotrophic factor (BDNF). This mechanism produces a rapid plasticity activation mediated by neurotransmitter homeostasis, synapse recovery, and increased dendritic spines and therefore, it is a promising therapeutic approach to improve cognitive symptoms in MDD.
Fil: Barrutieta Arberas, I.. Universidad del País Vasco; España
Fil: Ortuzar, N.. Universidad del País Vasco; España
Fil: Vaquero Rodríguez, A.. Universidad del País Vasco; España
Fil: Picó-Gallardo, M.. Universidad del País Vasco; España
Fil: Bengoetxea, H.. Universidad del País Vasco; España
Fil: Guevara, M. A.. Universidad Nacional de Cuyo; Argentina
Fil: Gargiulo, Pascual Angel. Universidad Nacional de Cuyo; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza; Argentina
Fil: Lafuente, J. V.. Universidad del País Vasco; España
Materia
BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF)
HIPPOCAMPUS (HC)
INTERNEURONS (INS)
KETAMINE
MAJOR DEPRESSIVE DISORDER (MDD)
N-METHYL-D-ASPARTATE RECEPTORS (NMDARS)
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/222316
Acceder
id CONICETDig_3f05ebb680537d2cea46bacd49a02f02
oai_identifier_str oai:ri.conicet.gov.ar:11336/222316
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling The role of ketamine in major depressive disorders: Effects on parvalbumin-positive interneurons in hippocampusBarrutieta Arberas, I.Ortuzar, N.Vaquero Rodríguez, A.Picó-Gallardo, M.Bengoetxea, H.Guevara, M. A.Gargiulo, Pascual AngelLafuente, J. V.BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF)HIPPOCAMPUS (HC)INTERNEURONS (INS)KETAMINEMAJOR DEPRESSIVE DISORDER (MDD)N-METHYL-D-ASPARTATE RECEPTORS (NMDARS)https://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Major depressive disorder (MDD) is a complex illness that is arising as a growing public health concern. Although several brain areas are related to this type of disorders, at the cellular level, the parvalbumin-positive cells of the hippocampus interplay a very relevant role. They control pyramidal cell bursts, neuronal networks, basic microcircuit functions, and other complex neuronal tasks involved in mood disorders. In resistant depressions, the efficacy of current antidepressant treatments drops dramatically, so the new rapid-acting antidepressants (RAADs) are being postulated as novel treatments. Ketamine at subanesthetic doses and its derivative metabolites have been proposed as RAADs due to their rapid and sustained action by blocking N-methyl-d-aspartate (NMDA) receptors, which in turn lead to the release of brain-derived neurotrophic factor (BDNF). This mechanism produces a rapid plasticity activation mediated by neurotransmitter homeostasis, synapse recovery, and increased dendritic spines and therefore, it is a promising therapeutic approach to improve cognitive symptoms in MDD.Fil: Barrutieta Arberas, I.. Universidad del País Vasco; EspañaFil: Ortuzar, N.. Universidad del País Vasco; EspañaFil: Vaquero Rodríguez, A.. Universidad del País Vasco; EspañaFil: Picó-Gallardo, M.. Universidad del País Vasco; EspañaFil: Bengoetxea, H.. Universidad del País Vasco; EspañaFil: Guevara, M. A.. Universidad Nacional de Cuyo; ArgentinaFil: Gargiulo, Pascual Angel. Universidad Nacional de Cuyo; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza; ArgentinaFil: Lafuente, J. V.. Universidad del País Vasco; EspañaSoc Experimental Biology Medicine2023-05info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/222316Barrutieta Arberas, I.; Ortuzar, N.; Vaquero Rodríguez, A.; Picó-Gallardo, M.; Bengoetxea, H.; et al.; The role of ketamine in major depressive disorders: Effects on parvalbumin-positive interneurons in hippocampus; Soc Experimental Biology Medicine; Experimental Biology And Medicine; 248; 7; 5-2023; 588-5951535-3702CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/http://journals.sagepub.com/doi/10.1177/15353702231170007info:eu-repo/semantics/altIdentifier/doi/10.1177/15353702231170007info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T09:51:00Zoai:ri.conicet.gov.ar:11336/222316instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 09:51:01.247CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv The role of ketamine in major depressive disorders: Effects on parvalbumin-positive interneurons in hippocampus
title The role of ketamine in major depressive disorders: Effects on parvalbumin-positive interneurons in hippocampus
spellingShingle The role of ketamine in major depressive disorders: Effects on parvalbumin-positive interneurons in hippocampus
Barrutieta Arberas, I.
BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF)
HIPPOCAMPUS (HC)
INTERNEURONS (INS)
KETAMINE
MAJOR DEPRESSIVE DISORDER (MDD)
N-METHYL-D-ASPARTATE RECEPTORS (NMDARS)
title_short The role of ketamine in major depressive disorders: Effects on parvalbumin-positive interneurons in hippocampus
title_full The role of ketamine in major depressive disorders: Effects on parvalbumin-positive interneurons in hippocampus
title_fullStr The role of ketamine in major depressive disorders: Effects on parvalbumin-positive interneurons in hippocampus
title_full_unstemmed The role of ketamine in major depressive disorders: Effects on parvalbumin-positive interneurons in hippocampus
title_sort The role of ketamine in major depressive disorders: Effects on parvalbumin-positive interneurons in hippocampus
dc.creator.none.fl_str_mv Barrutieta Arberas, I.
Ortuzar, N.
Vaquero Rodríguez, A.
Picó-Gallardo, M.
Bengoetxea, H.
Guevara, M. A.
Gargiulo, Pascual Angel
Lafuente, J. V.
author Barrutieta Arberas, I.
author_facet Barrutieta Arberas, I.
Ortuzar, N.
Vaquero Rodríguez, A.
Picó-Gallardo, M.
Bengoetxea, H.
Guevara, M. A.
Gargiulo, Pascual Angel
Lafuente, J. V.
author_role author
author2 Ortuzar, N.
Vaquero Rodríguez, A.
Picó-Gallardo, M.
Bengoetxea, H.
Guevara, M. A.
Gargiulo, Pascual Angel
Lafuente, J. V.
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF)
HIPPOCAMPUS (HC)
INTERNEURONS (INS)
KETAMINE
MAJOR DEPRESSIVE DISORDER (MDD)
N-METHYL-D-ASPARTATE RECEPTORS (NMDARS)
topic BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF)
HIPPOCAMPUS (HC)
INTERNEURONS (INS)
KETAMINE
MAJOR DEPRESSIVE DISORDER (MDD)
N-METHYL-D-ASPARTATE RECEPTORS (NMDARS)
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Major depressive disorder (MDD) is a complex illness that is arising as a growing public health concern. Although several brain areas are related to this type of disorders, at the cellular level, the parvalbumin-positive cells of the hippocampus interplay a very relevant role. They control pyramidal cell bursts, neuronal networks, basic microcircuit functions, and other complex neuronal tasks involved in mood disorders. In resistant depressions, the efficacy of current antidepressant treatments drops dramatically, so the new rapid-acting antidepressants (RAADs) are being postulated as novel treatments. Ketamine at subanesthetic doses and its derivative metabolites have been proposed as RAADs due to their rapid and sustained action by blocking N-methyl-d-aspartate (NMDA) receptors, which in turn lead to the release of brain-derived neurotrophic factor (BDNF). This mechanism produces a rapid plasticity activation mediated by neurotransmitter homeostasis, synapse recovery, and increased dendritic spines and therefore, it is a promising therapeutic approach to improve cognitive symptoms in MDD.
Fil: Barrutieta Arberas, I.. Universidad del País Vasco; España
Fil: Ortuzar, N.. Universidad del País Vasco; España
Fil: Vaquero Rodríguez, A.. Universidad del País Vasco; España
Fil: Picó-Gallardo, M.. Universidad del País Vasco; España
Fil: Bengoetxea, H.. Universidad del País Vasco; España
Fil: Guevara, M. A.. Universidad Nacional de Cuyo; Argentina
Fil: Gargiulo, Pascual Angel. Universidad Nacional de Cuyo; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza; Argentina
Fil: Lafuente, J. V.. Universidad del País Vasco; España
description Major depressive disorder (MDD) is a complex illness that is arising as a growing public health concern. Although several brain areas are related to this type of disorders, at the cellular level, the parvalbumin-positive cells of the hippocampus interplay a very relevant role. They control pyramidal cell bursts, neuronal networks, basic microcircuit functions, and other complex neuronal tasks involved in mood disorders. In resistant depressions, the efficacy of current antidepressant treatments drops dramatically, so the new rapid-acting antidepressants (RAADs) are being postulated as novel treatments. Ketamine at subanesthetic doses and its derivative metabolites have been proposed as RAADs due to their rapid and sustained action by blocking N-methyl-d-aspartate (NMDA) receptors, which in turn lead to the release of brain-derived neurotrophic factor (BDNF). This mechanism produces a rapid plasticity activation mediated by neurotransmitter homeostasis, synapse recovery, and increased dendritic spines and therefore, it is a promising therapeutic approach to improve cognitive symptoms in MDD.
publishDate 2023
dc.date.none.fl_str_mv 2023-05
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/222316
Barrutieta Arberas, I.; Ortuzar, N.; Vaquero Rodríguez, A.; Picó-Gallardo, M.; Bengoetxea, H.; et al.; The role of ketamine in major depressive disorders: Effects on parvalbumin-positive interneurons in hippocampus; Soc Experimental Biology Medicine; Experimental Biology And Medicine; 248; 7; 5-2023; 588-595
1535-3702
CONICET Digital
CONICET
url http://hdl.handle.net/11336/222316
identifier_str_mv Barrutieta Arberas, I.; Ortuzar, N.; Vaquero Rodríguez, A.; Picó-Gallardo, M.; Bengoetxea, H.; et al.; The role of ketamine in major depressive disorders: Effects on parvalbumin-positive interneurons in hippocampus; Soc Experimental Biology Medicine; Experimental Biology And Medicine; 248; 7; 5-2023; 588-595
1535-3702
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/http://journals.sagepub.com/doi/10.1177/15353702231170007
info:eu-repo/semantics/altIdentifier/doi/10.1177/15353702231170007
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Soc Experimental Biology Medicine
publisher.none.fl_str_mv Soc Experimental Biology Medicine
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844613570479783936
score 13.070432

Publicaciones similares